Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Oncolytics Biotech Inc T.ONC

Alternate Symbol(s):  ONCY

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and... see more

TSX:ONC - Post Discussion

Oncolytics Biotech Inc > Goblet abstract
View:
Post by jh1970 on Jan 21, 2025 5:17pm

Goblet abstract

Results:Twelve patients are currently evaluable for tumor response in the SCCA cohort. Four out of 12 patients have achieved an objective response to therapy including 1 prolonged complete response (>15 months) and 3 partial responses- resulting in an ORR of 33.3%. Final ORR, progression-free survival, and overall survival results are pending. The DSMB has identified no safety signals and has recommended that enrollment continues without modification. TIL clonal expansion in the blood has been observed at treatment cycle 4 in all 3 responding patients for whom data are available.

 

Conclusions:Twelve patients are currently evaluable for tumor response in the SCCA cohort. Four out of 12 patients have achieved an objective response to therapy including 1 prolonged complete response (>15 months) and 3 partial responses resulting in an ORR of 33.3%. Final ORR, progression-free survival, and overall survival results are pending. The DSMB has identified no safety signals and has recommended that enrollment continues without modification. TIL clonal expansion in the blood has been observed at treatment cycle 4 in all 3 responding patients for whom data are available.
Comment by CMHarring218431 on Jan 21, 2025 5:40pm
That's it ? Wow. Glad I bought more this am. Not
Comment by canadafan on Jan 21, 2025 5:46pm
Not sure what you are reading as in " not" A 33% response including a complete response greater than 15 months is very good news. very early, yes. however, recommending to continue on, is an additional endorsement. all the trials have limits set to be met. assuming those limits are not met, the trials end. in simple terms, the limits were met. tondetermin how valuable etc, needs further ...more  
Comment by inthno on Jan 21, 2025 6:16pm
Depends how u look at it compares to the original anal release results where we had the complete response and 2 Orr for a 37% rate. So basically from what we know we have added 1 additional patient with a pr so it would appear. Of course either Roche and or the market will dictate how good these results are and we should know soon enough.
Comment by Buckhenry on Jan 21, 2025 7:30pm
Don't be overly surprised if we don't hear anything. This company is good at kicking the can down the road. But I secretly hope we get some good news. Don't tell the woke pumpers here...
Comment by CMHarring218431 on Jan 21, 2025 8:44pm
Cause it is not enough to move the needle. If what Oncy has is not enough to entice BP, how will this do it?